AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals (TLPH) is a small-cap specialty pharmaceutical company focused on treatments for acute pain. The company’s market cap is modest, which typically signals higher volatility and sensitivity to clinical, regulatory and commercial developments. AcelRx has pursued sufentanil-based products intended for hospital and procedural pain management; its prospects depend on product approvals, hospital uptake, reimbursement and any licensing or partnership deals. Financially, smaller biopharma firms often face cash‑burn and may need to raise capital, which can dilute shareholders. For investors, the appeal lies in potential upside from successful commercialisation or strategic partnerships, but there are clear risks: regulatory setbacks, limited revenue history, competitive alternatives and funding needs. This profile is educational only, not personalised advice. Consider whether a speculative, high-risk biopharma investment fits your objectives and risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AcelRx's stock with a target price of $4.42, indicating strong growth potential.
Financial Health
AcelRx Pharmaceuticals has low revenue and limited cash flow, indicating financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TLPH
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial potential
Products aimed at acute pain could address hospital procedural needs; uptake depends on clinician adoption and reimbursement, though outcomes can vary.
Regulatory sensitivity
Clinical and approval milestones have outsized impact on the share price; regulatory setbacks or delays are a common risk.
Partnering and funding
Partnerships or licensing deals can accelerate reach and reduce costs, but the company may also need to raise capital, which can dilute investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
